Industry News

Drug Tariff Update
  Tuesday, January 26, 2016

Drug Tariff Update

February 2016

Effective from 1st February

3 new products have been added to Drug Tariff Part VIIIB Specials:


  • Acetylcysteine 10% eye drops
  • Atropine 500micrograms/5ml oral solution
  • Pyridostigmine bromide 60mg/5ml oral suspension

1 product has been removed from Drug Tariff Part VIIIB Specials:

  • Pilocarpine hydrochloride 0.5% eye drops  10ml

Click here to download the latest specials Drug Tariff price list.

Drug Tariff Update
  Tuesday, December 01, 2015

Drug Tariff Update

December 2015

Effective from 1st December 2015

The following lines have been moved from part VIIIB to part VIIIA as they have been licensed.

  • Methotrexate 10mg/5ml Solution 
  • Methotrexate 10mg/5ml Suspension 

Customer Announcement
  Monday, November 16, 2015

Customer Announcement

Invoice Stickers

Further to the announcement from the National Pharmacy Association, advising pharmacy contractors not to use invoice stickers for endorsing purposes, IPS Specials would like to reassure all of their customers that issues described by the NPA in their statement do not apply to IPS’ invoice stickers. IPS would like to advise all customers to carry on using the innovative endorsement tool as usual.

Designed to fit perfectly in the endorsement area of the prescription, our innovative stickers vastly reduce the probability of endorsement error, ensuring that pharmacies get paid the correct amount for their specials.

Read the rest of entry »

Scottish Drug Tariff Update
  Monday, November 02, 2015

Scottish Drug Tariff Update

November 2015

Effective from 1st November 2015

There are 75 lines on Part 7S effective from 1st November 2015

16 prices have gone up and 26 prices have gone down.

Click here to download the latest Part 7S drug tariff.

Read the rest of entry »

Drug Tariff Update
  Tuesday, October 27, 2015

Drug Tariff Update

November 2015

Effective from 1st November

  • 249 products in Part VIIIB
  • 51 minimum volume prices have gone up
  • 185 minimum volume prices have gone down
  • 12 New Products
  • 5 Products Removed
  • 1 Product Replaced

Read the rest of entry »

Drug Tariff Update
  Wednesday, July 22, 2015

Drug Tariff Update

August 2015

Effective from 1st August 2015

The following 5 lines have been added to Part VIIIB:

  • Eosin 2% solution
  • Naltrexone 5mg/5ml oral solution
  • Salicylic acid 20% ointment
  • Salicylic acid 5% ointment
  • Topiramate 100mg/5ml oral suspension   

Drug Tariff Update
  Monday, June 29, 2015

Drug Tariff Update

July 2015

Effective from 1st July 2015

The following 2 lines have been added to Part VIIIA as they are now licensed.

Amlodipine 10mg/5ml oral solution sugar free 150ml

Amlodipine 5mg/5ml oral solution sugar free 150ml

As a result, the following 4 lines have been removed from Part VIIB:

  • Amlodipine 10mg/5ml oral solution
  • Amlodipine 10mg/5ml oral suspension
  • Amlodipine 5mg/5ml oral solution
  • Amlodipine 5mg/5ml oral suspension

IPS Specials will continue providing Amlodipine suspension as a Non-DT product effective from 1st July - provided there is clinical need.

Drug Tariff Update
  Monday, April 20, 2015

Drug Tariff Update

May 2015

May 2015 Drug Tariff Part VIIIB Specials



Amiodarone 100mg/5ml oral solution



Bisoprolol 1.25mg/5ml oral solution



Coal tar 10% ointment

All bases

Read the rest of entry »

Drug Tariff Update
  Monday, February 02, 2015

Drug Tariff Update

February 2015

The updated Specials Drug Tariff (Part VIIIB) has been released and includes a number of price changes.

Arginine 2g/5ml oral solution STD, SF, FF 250ml £139.72 56p per ML has been added to the Specials Drug Tariff Part VIIIB in England & Wales.

Three products have been removed:

  • Amitriptyline 10mg/5ml oral solution - Now Licensed
  • Sodium bicarbonate 420mg/5ml (1mmol/ml) oral solution - Now Licensed
  • Sodium bicarbonate 420mg/5ml (1mmol/ml) oral solution - Now Licensed

APSM White Paper
  Monday, January 12, 2015

APSM White Paper

January 2015


The APSM has launched a White Paper which attributes an economic value to the provision of unlicensed medicines within the NHS.

The Paper takes a series of typical patient scenarios where a Special is indicated and then identifies the potential cost to the NHS of attempting to meet patient need with a lower cost, higher risk alternative such as tablet crushing.

The White Paper was commissioned in the light of growing concern about cost pressures leading to higher risk practice in the supply chain.

There is regulation and guidance to prevent unnecessary prescribing of a Special and as an industry we have a duty to support this. However, when a Special is indicated, Specials should be manufactured in an MHRA-approved facility wherever possible.

You can read the APSM's White Paper here

Call us now 0800 644 0747
Terms Of Use|Privacy Statement| Copyright 2018 IPS Specials